IJCS | Volume 31, Nº3, Maio / Junho 2018

315 1. Task Force Members. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014; 35(39): 2733–79. DOI: 10.1093/euheartj./Orgv-Ejehu284. 2. Lipshultz SE, Sleeper LA, Towbin JA, lowe AM, Cox GF, Lurie PR, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. NEngl J Med. 2003;348(17):1647-55. DOI: 10.1056/NEJM.oa21715. 3. Ho CY, Charron P, Richard P, Garolami F, Van Spaendonck-Zwarts KY, Pinto Y. Genetic advances in sarcomeric cardiomyopathies: state of the art. Cardiovasc Res 2015; 105: 397–408. DOI: 10.1093/ cv/cvv025. 4. Anan R, ShonoH, Kisanuki A, Arima S, Nakao S, Tanaka H. et al. Patients with familial hypertrophiccardiomyopathy caused by a Phe110Ile missense mutation in the cardiactroponin T gene have variable cardiac morphologies and a favorableprognosis. Circulation. 1998;98(5):391–7. PMID:9714088. 5. Kubo T, Gimeno JR, Bahl A, Steffenson U, Osman E, Thaman R, et al.Prevalence, Clinical Significance,and Genetic Basis of Hypertrophic Cardiomyopathy With Restrictive Phenotype. J Am Coll Cardiol 2007;49(25):2419–26. DOI: 10.1016/jack.2007.02061. 6. Harris JK, Spirito P, MaronMS, zenovichAG, Formisano F, Lesser JR, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy.Circulation. 2006;114(3):216 –25. DOI: 10.1161./CIRCULATIONAHA.105.583.500. Referências Arias et al. Cardiomiopatia hipertrófica International Journal of Cardiovascular Sciences. 2018;31(3)312-315 Relato de Caso